Sandoz reports strong 2024 results

Swiss generics and biosimilars giant Sandoz (SIX: SDZ) today announced financial results for the full year 2024, showing that sales were$10.4 billion, up by 9% in constant currencies (+7% in $). Fourth-quarter net sales of $2.7 billion, up by 9% in constant currencies (+7% in $).

The majority of revenues came for generics, which came in at $7,504 million (+1% YoY, +2% CER), with biosimilars sales of $2,853(+29% YoY, +30% CER). Strong sales performances in all three regions, was driven by double-digit growth in biosimilars, both in the fourth quarter and full year, benefitting from recent launches and base-business momentum

Operating income of $307 million, was up by 5% in constant currencies (-18% in $). Core earnings before interest, tax, depreciation and amortization (EBITDA) were $2.08 billion, up 24% (+19 in $).